Bioversys N Logo

Bioversys N

Develops novel therapeutics to combat antimicrobial resistance in life-threatening infections.

BIOV | SW

Overview

Corporate Details

ISIN(s):
CH0210362643 (+1 more)
LEI:
894500UFIGC75NPZEZ68
Country:
Switzerland
Address:
Hochbergerstrasse 60C, 4057 Basel
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Bioversys is a clinical-stage biopharmaceutical company dedicated to the research and development of novel small-molecule therapeutics to combat the global threat of Antimicrobial Resistance (AMR). The company specializes in developing drugs that utilize novel modes of action to target life-threatening, drug-resistant bacteria. Its clinical pipeline addresses high-priority pathogens and includes candidates for serious hospital-acquired infections (BV100), multi-drug resistant Tuberculosis (Alpibectir), and S. aureus infections (BV200). By targeting novel bacterial pathways, Bioversys aims to provide innovative solutions for significant unmet medical needs in infectious diseases.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-10 07:00
Earnings Release
Bioversys reports corporate highlights and key financials for the first half 20…
English 24.8 KB
2025-09-10 02:00
Earnings Release
Bioversys reports corporate highlights and key financials for the first half 20…
English 23.3 KB
2025-09-10 00:00
Interim Report
BioVersys Half Year Report 2025
English 1.8 MB
2025-08-27 07:00
Regulatory News Service
BioVersys receives EMA Orphan Designation for the combination of alpibectir and…
English 21.9 KB
2025-08-27 02:00
Regulatory News Service
BioVersys receives EMA Orphan Designation for the combination of alpibectir and…
English 15.9 KB
2025-07-02 07:00
M&A Activity
BIOVERSYS AND SHIONOGI ENTER INTO GLOBAL RESEARCH COLLABORATION FOR BROAD-SPECT…
English 21.3 KB
2025-07-02 02:00
M&A Activity
BIOVERSYS AND SHIONOGI ENTER INTO GLOBAL RESEARCH COLLABORATION FOR BROAD-SPECT…
English 16.1 KB
2025-06-30 07:00
Post-Annual General Meeting Information
BIOVERSYS ANNOUNCES RESULTS FROM its ANNUAL GENERAL MEETING OF SHAREHOLDERS
English 10.5 KB
2025-06-30 02:00
Post-Annual General Meeting Information
BIOVERSYS ANNOUNCES RESULTS FROM its ANNUAL GENERAL MEETING OF SHAREHOLDERS
English 6.9 KB
2025-06-03 07:00
Pre-Annual General Meeting Information
BioVersys publishes Invitation to its ANNUAL GENERAL MEETING OF SHAREHOLDERS 20…
English 11.6 KB
2025-06-03 02:00
Pre-Annual General Meeting Information
BioVersys publishes Invitation to its ANNUAL GENERAL MEETING OF SHAREHOLDERS 20…
English 11.0 KB
2025-04-30 00:00
Investor Presentation
BioVersys Corporate Presentation
English 3.2 MB
2025-04-28 07:00
Regulatory News Service
BioVersys to Host Virtual KOL Event to Discuss BV100 Phase 2 Ventilator Associa…
English 8.5 KB
2025-04-28 02:00
Report Publication Announcement
BioVersys to Host Virtual KOL Event to Discuss BV100 Phase 2 Ventilator Associa…
English 7.2 KB
2025-04-08 07:00
Regulatory News Service
BIOVERSYS TO PRESENT BV100 PHASE 2 DATA AT 35TH ESCMID GLOBAL 2025
English 29.7 KB

Automate Your Workflow. Get a real-time feed of all Bioversys N filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Bioversys N via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
KANABO GROUP PLC Logo
Develops cannabis formulas and vaporization devices for the medical and consumer wellness markets.
United Kingdom KNB
Kancera Logo
Develops small molecule drugs targeting the fractalkine axis for cancer and inflammatory diseases.
Sweden KAN
KANGSTEM BIOTECH CO., LTD. Logo
Develops stem cell therapies for rare diseases; offers culture media, cell platforms, and CDMO services.
South Korea 217730
Karo Pharma AB Logo
Develops and sells everyday healthcare products, focusing on OTC and skin health in Europe.
Sweden KARO
KBIO COMPANY Inc. Logo
Using a plant-based platform to rapidly develop biologics for public health.
South Korea 038530
Keeps Biopharma Inc. Logo
Develops cancer therapies and obesity drugs; manufactures industrial and cleanroom products.
South Korea 256940
Kidswell Bio Corporation Logo
Biopharma R&D of biosimilars, biologics, and cell therapies, with a pediatric focus.
Japan 4584
Kinarus Therapeutics Holding AG Logo
A specialty pharma firm developing and selling medicines for rare and specialty diseases.
Switzerland KNRS
KISSEI PHARMACEUTICAL CO.,LTD. Logo
Develops innovative drugs for urology, renal diseases, and rare or intractable diseases.
Japan 4547
Klaria Pharma Holding AB Logo
Develops oral films for non-invasive drug delivery as an alternative to injections and sprays.
Sweden KLAR

Talk to a Data Expert

Have a question? We'll get back to you promptly.